A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
Min Ho Park(Kyung Hee University), Joon Jeong(Yonsei University), Woo Chul Noh(Korea Institute of Radiological and Medical Sciences), Young Bum Yoo(Konkuk University Medical Center), Jinsun Lee(University of California San Diego), Ju Yeon Kim(Gyeongsang National University), Gil Soo Son(Korea University), Soo Jung Lee(Pusan National University Hospital), Geumhee Gwak(Inje University Sanggye Paik Hospital), Tae Hyun Kim(Inje University Busan Paik Hospital), Min Young Kim(Dongnam Institute of Radiological & Medical Sciences), Hyun‐Ah Kim(Korea University), Sung Soo Kang(CHA University), Young Jin Suh(The Catholic University of Korea St. Vincent's Hospital), Chang Wan Jeon(Kosin University Gospel Hospital), Seok Won Lee(Pusan National University Hospital), Byung-In Moon(Ewha Womans University)
Cited by 2
Related Papers
Immune Escape in Breast Cancer During <i>In Situ</i> to Invasive Carcinoma Transition
|Cancer Discovery|2017|242
Anticancer Activity of Pristimerin in Epidermal Growth Factor Receptor 2-Positive SKBR3 Human Breast Cancer Cells
|Biological and Pharmaceutical Bulletin|2013|54
Combination of pristimerin and paclitaxel additively induces autophagy in human breast cancer cells via ERK1/2 regulation
|Molecular Medicine Reports|2018|47
Honokiol induces apoptosis and suppresses migration and invasion of ovarian carcinoma cells via AMPK/mTOR signaling pathway
|International Journal of Molecular Medicine|2019|39
Genomic Alterations during the <i>In Situ</i> to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System
|Molecular Cancer Research|2020|38